IQM-QUANTUM-COMPUTERS
7.4.2022 17:23:05 CEST | Business Wire | Press release
IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005722/en/
IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.
The purpose of the cooperation is to provide the researchers at the Hebrew University of Jerusalem (in the group led by Professor Nadav Katz within its Physics Department and Quantum Information Science Center) and Bar-Ilan University (in the group led by Professor Michael Stern, of the Department of Physics) commercial-grade quantum-computing hardware developed by IQM. Researchers in these groups will conduct experiments using the IQM hardware and further advance scientific development.
The initiative also includes testing IQM’s qubit technology and conducting experiments based on its hardware. This long-term cooperation will result in significant scientific breakthroughs, several academic contributions and new product innovations. This is in line with IQM’s chosen strategy of providing its customers and partners direct access to hardware components.
Speaking about this announcement, Dr. Juha Vartiainen, COO and cofounder of IQM, said, “We are very happy to be working with both the Hebrew University of Jerusalem and Bar-Ilan University and look forward to a fruitful, long-term scientific and commercial cooperation. This announcement aligns well with our strategy to provide commercial-grade quantum-computing hardware to global research groups.”
“This cooperation is also a significant milestone for our cooperation with the world-class quantum ecosystem in Israel. As quantum computers develop further, the know-how developed in Israel—for example, around machine learning and quantum software—is going to become more critical in the future,” added Juha.
In the future, all parties also aim to extend the collaboration toward building full-stack quantum computers for scientific and commercial purposes in Israel.
“We are excited about this new collaboration with IQM and have already measured several consistently high-coherence IQM devices in our lab in Israel. This is just the beginning of a productive and fruitful joint venture,” shared Prof. Nadav Katz, director of HUJI’s Quantum Information Science Center.
Highly coherent controlled oscillations of IQM’s qubits measured in Israel (HUJI).
“We are proud to take part in a study that places Israel and its universities at the forefront of the global effort to develop quantum computers. The road is still long, but I believe that we at Bar-Ilan, together with our partners at the Hebrew University, will succeed in achieving groundbreaking results,” said Prof. Michael Stern.
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has over 160 employees with offices in Paris, Bilbao, Munich and Espoo.
For more information: www.meetiqm.com
Recent IQM announcements:
- BioNTech Chief Operating Officer Dr. Sierk Poetting is to steer IQM global expansion as chairman .
- IQM continues its European expansion; the new French subsidiary will focus on IQM’s co-design customers in aviation, space and cybersecurity.
- IQM has opened its exclusive quantum fabrication facility in Finland.
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
About the Hebrew University of Jerusalem:
The Hebrew University of Jerusalem (HUJI) is Israel’s leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses. Founded in 1918 by luminaries including Albert Einstein, Chaim Weizmann, Sigmund Freud and Martin Buber, HUJI is ranked in the top echelon of the world’s leading universities. To date, HU faculty and alumni have won 8 Nobel Prizes, 1 Fields Medal and 1 Abel Prize—a proud tradition of innovation and excellence.
About Bar-Ilan University:
Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, uniquely combining cutting-edge scientific research with education steeped in Jewish values and social responsibility. Having grown from 70 students to close to 20,500 students, its milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
